Evidence map›Paper›PMID 32448342›Full record

ArticleBMC cancer2020

Cancer risks in Lynch syndrome, Lynch-like syndrome, and familial colorectal cancer type X: a prospective cohort study.

Karolin Bucksch, Silke Zachariae, Stefan Aretz, Reinhard Büttner, Elke Holinski-Feder, Stefanie Holzapfel, Robert Hüneburg, Matthias Kloor, Magnus von Knebel Doeberitz, Monika Morak and 13 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 2 pooled it
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 50 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Clinicopathological characteristics of Lynch-like syndrome.International journal of clinical oncology · 2024
    Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Global medical genetics · 2023
    Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 11 institutions in 1 country.

Karolin BuckschInstitute for Medical Informatics, Statistics and Epidemiology (IMISE), University of Leipzig, Leipzig, Germany. karolin.bucksch@imise.uni-leipzig.de.ORCID http://orcid.org/0000-0003-4586-4032
Silke ZachariaeInstitute for Medical Informatics, Statistics and Epidemiology (IMISE), University of Leipzig, Leipzig, Germany.
Stefan AretzInstitute of Human Genetics, University of Bonn, Bonn, Germany.
Reinhard BüttnerInstitute of Pathology, University of Cologne, Cologne, Germany.
Elke Holinski-FederMedizinische Klinik und Poliklinik IV, Campus Innenstadt, Klinikum der Universität München, Munich, Germany.
Stefanie HolzapfelInstitute of Human Genetics, University of Bonn, Bonn, Germany.
Robert HüneburgNational Center for Hereditary Tumor Syndromes, University Hospital Bonn, Bonn, Germany.
Matthias KloorDepartment of Applied Tumour Biology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Magnus von Knebel DoeberitzDepartment of Applied Tumour Biology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Monika MorakMedizinische Klinik und Poliklinik IV, Campus Innenstadt, Klinikum der Universität München, Munich, Germany.
Gabriela MösleinCenter for Hereditary Tumors, HELIOS Klinikum Wuppertal, University Witten-Herdecke, Wuppertal, Germany.
Jacob NattermannNational Center for Hereditary Tumor Syndromes, University Hospital Bonn, Bonn, Germany.
Claudia PerneInstitute of Human Genetics, University of Bonn, Bonn, Germany.
Nils RahnerInstitute of Human Genetics, Medical Faculty, Heinrich-Heine-University, Düsseldorf, Germany.
Wolff SchmiegelDepartment of Medicine, Knappschaftskrankenhaus, Ruhr-University Bochum, Bochum, Germany.
Karsten SchulmannDepartment of Hematology and Oncology, Klinikum Hochsauerland, Meschede, Germany.
Verena Steinke-LangeMedizinische Klinik und Poliklinik IV, Campus Innenstadt, Klinikum der Universität München, Munich, Germany.
Christian P StrassburgNational Center for Hereditary Tumor Syndromes, University Hospital Bonn, Bonn, Germany.
Deepak B VangalaDepartment of Medicine, Knappschaftskrankenhaus, Ruhr-University Bochum, Bochum, Germany.
Jürgen WeitzDepartment of Surgery, Technische Universität Dresden, Dresden, Germany.
Markus LoefflerInstitute for Medical Informatics, Statistics and Epidemiology (IMISE), University of Leipzig, Leipzig, Germany.
Christoph EngelInstitute for Medical Informatics, Statistics and Epidemiology (IMISE), University of Leipzig, Leipzig, Germany.
German Consortium for Familial Intestinal Cancer
Leipzig University · DELMU Klinikum · DEUniversity Hospital Bonn · DEUniversity of Bonn · DEGerman Cancer Research Center · DEUniversitätsklinikum Knappschaftskrankenhaus Bochum · DEHeinrich Heine University Düsseldorf · DEHelios Universitätsklinikum Wuppertal · DEKlinikum Arnsberg · DETechnische Universität Dresden · DEUniversity of Cologne · DE

Funding

Deutsche Krebshilfe 70-2706-Lö 1, 70-2706 / 107015, 108445, 108913, 111008
6 · The paper itself

Abstract

backgroundIndividuals with pathogenic germline variants in DNA mismatch repair (MMR) genes are at increased risk of developing colorectal, endometrial and other cancers (Lynch syndrome, LS). While previous studies have extensively described cancer risks in LS, cancer risks in individuals from families without detectable MMR gene defects despite MMR deficiency (Lynch-like syndrome, LLS), and in individuals from families fulfilling the Amsterdam-II criteria without any signs of MMR deficiency (familial colorectal cancer type X, FCCX) are less well studied. The aim of this prospective study was to characterise the risk for different cancer types in LS, LLS, and FCCX, and to compare these with the cancer risks in the general population.

methodsData was taken from the registry of the German Consortium for Familial Intestinal Cancer, where individuals were followed up prospectively within the framework of an intensified surveillance programme at recommended annual examination intervals. A total of 1120 LS, 594 LLS, and 116 FCCX individuals were analysed. From this total sample, eight different cohorts were defined, in which age-dependent cumulative risks and standardised incidence ratios were calculated regarding the first incident occurrence of any, colorectal, stomach, small bowel, urothelial, female breast, ovarian, and endometrial cancer, separately for LS, LLS, and FCCX.

resultsThe number of individuals at risk for first incident cancer ranged from 322 to 1102 in LS, 120 to 586 in LLS, and 40 to 116 in FCCX, depending on the cancer type of interest. For most cancer types, higher risks were observed in LS compared to LLS, FCCX, and the general population. Risks for any, colorectal, stomach, urothelial, and endometrial cancer were significantly higher in LLS compared to the general population. No significantly increased risks could be detected in FCCX compared to LLS patients, and the general population. Colorectal and endometrial cancer risks tended to be higher in LLS than in FCCX.

conclusionsThe characterisation of cancer risks in patients with LLS and FCCX is important to develop appropriate surveillance programmes for these specific intermediate risk groups. Larger prospective studies are needed to obtain more precise risk estimates.

Indexed as

Genetic Predisposition to DiseaseGenetics, PopulationAdultAgedAged, 80 and overBiomarkers, TumorBrain NeoplasmsColorectal NeoplasmsDNA Mismatch RepairDNA Repair EnzymesFemaleFollow-Up StudiesHumansMaleMicrosatellite InstabilityMiddle AgedBiomarkers, TumorDNA Repair EnzymesCancer riskFamilial colorectal cancer type XLynch-like syndromeLynch syndromeProspective surveillance study

Identifiers

PMID32448342
PMCPMC7245918
OpenAlexW3026335404

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.